Sentynl Therapeutics Advances Progeria Treatment with New Licensing Deal Sentynl Therapeutics has signed an agreement with PRG S&T to license Progerinin, a potential treatment for Hutchinson-Gilford Progeria Syndrome, enhancing its commitment to rare disease solutions.

Sentynl Therapeutics Advances Progeria Treatment with New Licensing Deal #United_States #Solana_Beach #Progeria #Sentynl #Progerinin